Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: A 5-year follow-up of 150 patients - Wikidata - wikimedia - TriplyDB

Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: A 5-year follow-up of 150 patients

Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: A 5-year follow-up of 150 patients

http://www.wikidata.org/entity/Q27489398

about

New advances in hepatocellular carcinoma Atherosclerosis as Extrahepatic Manifestation of Chronic Infection with Hepatitis C Virus Clinical Advances in Fibrosis Progression of Chronic Hepatitis B and C A New Twist to a Chronic HCV Infection: Occult Hepatitis C Prediction of fibrosis progression in chronic viral hepatitis Emerging therapies for hepatitis C Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis A comprehensive long-term prognosis of chronic hepatitis C patients with antiviral therapy: a meta-analysis of studies from 2008 to 2014 Genome-wide association study identifies a PSMD3 variant associated with neutropenia in interferon-based therapy for chronic hepatitis C Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C Virologic Cure of Hepatitis C: Impact on Hepatic Fibrosis and Patient Outcomes.Non-invasive evaluation of liver stiffness after splenectomy in rabbits with CCl4-induced liver fibrosis Diagnostic Accuracy of Acoustic Radiation Force Impulse (ARFI) in Diagnosis of Liver Fibrosis among Egyptian Patients with Chronic HCV Infection Changes of shear-wave velocity by interferon-based therapy in chronic hepatitis C.Improvement of thrombocytopenia in hepatitis C-related advanced fibrosis patients after sustained virological response.Role of ITPA gene polymorphism in ribavirin-induced anemia and thrombocytopenia in Egyptian patients with chronic hepatitis C.Factors associated with success of telaprevir- and boceprevir-based triple therapy for hepatitis C virus infection.Evaluated outcomes in patients with Chronic Hepatitis C.Oxidative stress and hepatic Nox proteins in chronic hepatitis C and hepatocellular carcinoma.Trace amounts of sporadically reappearing HCV RNA can cause infection Image analysis of liver collagen using sirius red is more accurate and correlates better with serum fibrosis markers than trichrome.Outcome of sustained virological responders with histologically advanced chronic hepatitis C.Longitudinal changes of the laboratory data of chronic hepatitis C patients with sustained virological response on long-term follow-up.Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more.Similar progression of fibrosis between HIV/HCV-infected and HCV-infected patients: Analysis of paired liver biopsy samples.Reproductive status is associated with the severity of fibrosis in women with hepatitis C.Long-term effects of antiviral therapy in patients with chronic hepatitis C.Long-term outcome of chronic hepatitis C patients with sustained virological response to peginterferon plus ribavirin Epigenetic signatures of alcohol abuse and hepatitis infection during human hepatocarcinogenesis.Predictors of spontaneous viral clearance and outcomes of acute hepatitis C infection Protein kinase expression as a predictive factor for interferon response in chronic hepatitis C patients Persistence of hepatitis C virus during and after otherwise clinically successful treatment of chronic hepatitis C with standard pegylated interferon α-2b and ribavirin therapy Analysis of interferon signaling by infectious hepatitis C virus clones with substitutions of core amino acids 70 and 91 Influence of genes suppressing interferon effects in peripheral blood mononuclear cells during triple antiviral therapy for chronic hepatitis C.The factors associated with longitudinal changes in liver stiffness in patients with chronic hepatitis B.Outcomes of chronic hepatitis C therapy in patients treated in community versus academic centres in Canada: final results of APPROACH (a prospective study of peginterferon alfa-2a and ribavirin at academic and community centres in Canada).The impact of antiviral therapy and the influence of metabolic cofactors on the outcome of chronic HCV infection.Durability of a sustained virological response in chronic hepatitis C patients treated with pegylated interferon alfa and ribavirin.A pilot training program for a motivational enhancement approach to hepatitis C virus treatment among individuals in Israeli methadone treatment centers.

P2860

Q26749329-3DC43871-3BB7-4C3A-A84F-6CC13765E162 Q26765245-471C00A3-359F-4EA2-A4EF-871648C7039D Q26781789-ACCC4616-ADFE-46EC-BD7B-3BB1C02576A1 Q26798189-13A95783-04B8-491E-8898-72303DEDBB81 Q26823671-B8A19AD4-575C-47AF-B802-1DBD4E10B83F Q26853642-1F596ECF-C629-44D9-8757-0EC681907D67 Q28076352-FE7EDDE2-8B2E-43B1-827A-327F3AAD2B92 Q28081137-35142CA7-3031-4031-8646-73059A931094 Q28254011-9670E608-BC60-451A-B74A-239A00EF0268 Q28943467-8941F873-E5ED-489E-B005-76B25739E674 Q30235178-06A71BEE-3422-4ED5-BEDA-82CD37AB3AC2 Q30250322-142353F6-6FC6-4A95-A083-A25346735BB6 Q30367357-D5C39FAE-8E82-4038-9F53-485F170FFEA5 Q30372945-4FCB5DDD-44B4-4BAB-972B-F3C7C7BDE96E Q30402571-3BE3CF19-08B6-4DF4-AF1C-14B811A1158B Q33403491-1B355B2D-1F62-473C-BD5A-785D47489A06 Q33430028-54A25C20-8753-465C-812A-674BC4FEA73F Q33576531-6B86D396-1D2F-4B16-B8DC-F54D7F3C4545 Q33596752-F58FCC4E-2C9E-483B-96EF-AB810E172369 Q33904328-CD407D8B-45EC-45CD-95FF-C63183CE8031 Q33944273-542BC5BC-0796-4CCF-85C6-CF6329901A17 Q34036477-A95D5368-28E9-405A-B4DF-1D8AB60C4D7B Q34101701-3715D497-C8AD-48BF-A094-9404FED77427 Q34125554-C5B81FCC-DC8E-4A74-B771-8CB73448AD2B Q34172595-D2DD57AF-DF25-4018-81DE-E2DD48FA3D80 Q34380399-A7B893F3-85B0-495A-B644-405826162357 Q34412627-793BEE27-D356-4C00-8CD0-12AB5E981B62 Q34415157-BD9F84FE-D858-4362-B1F8-AEBAF4E3482F Q34521418-608A3535-7B58-488C-9539-30577DD755C4 Q34619389-C11359EF-A206-4D88-8D17-97FB9F50339E Q34779758-44041D5A-F9DF-4349-84D8-4A4D049AD01E Q34961241-263DDFC0-87F2-47F9-89C1-BDC31634CE8A Q35053440-FD656598-3786-4111-8451-A11CFCAD1E1C Q35077047-CC41093C-2CB0-4577-BED9-D06946999394 Q35112598-3CD2084A-C0DB-4243-A0B3-253E4F767DBD Q35231817-8AD9356A-3E4F-4D7F-B018-32D18FD66834 Q35453012-3DA52602-F224-4C1B-8DB7-8A9A11855EF4 Q35590977-D666BC52-FEC9-4B2D-9EA5-7E922B445F60 Q35833191-2E2C66FD-C74D-4142-BEC6-AB5B62052F11 Q35834617-3DB5227E-9551-4D37-84C9-FADB1E53B2B3

P2860

Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: A 5-year follow-up of 150 patients

http://www.wikidata.org/entity/Q27489398

description

2009 nî lūn-bûn

@nan

2009 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի մարտին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Clinical, virologic, histologi ...... year follow-up of 150 patients

@ast

Clinical, virologic, histologi ...... year follow-up of 150 patients

@en

Clinical, virologic, histologi ...... year follow-up of 150 patients

@nl

type

label

Clinical, virologic, histologi ...... year follow-up of 150 patients

@ast

Clinical, virologic, histologi ...... year follow-up of 150 patients

@en

Clinical, virologic, histologi ...... year follow-up of 150 patients

@nl

prefLabel

Clinical, virologic, histologi ...... year follow-up of 150 patients

@ast

Clinical, virologic, histologi ...... year follow-up of 150 patients

@en

Clinical, virologic, histologi ...... year follow-up of 150 patients

@nl

P1433

Q27489398-06AE4D15-298A-42DF-B1FA-3E5E465986D0

P1476

Q27489398-B2B46DF0-731A-4B5E-A390-1A59934AE192

P2093

Q27489398-4A4B8C4B-B399-4AF6-AAD4-B1A1819787B2

Q27489398-83954B1F-6C09-4037-AD57-73F392A66240

Q27489398-BCA7FD74-C018-41AB-A064-5A0FF010206C

Q27489398-D8BA5D32-46A2-4542-B292-1DF9399E8226

Q27489398-F4BDD791-AF01-4BB8-B819-AB938DDA1FDC

P2860

Q27489398-0351190D-45B9-4E1F-9662-B53155CAADF7

Q27489398-0ADE7C7E-6130-488A-9112-C47C82796499

Q27489398-1F7786F6-9221-4B23-9A53-8E552C79192D

Q27489398-3B4BC5FB-A1F6-4C51-BC82-797BB61D28D3

Q27489398-3D7AB78C-B6A7-4F9C-8642-ECA10AB6136A

Q27489398-404687DD-0C63-401C-AC19-E9C48C42D8B5

Q27489398-4ABC4E8E-0EA2-444F-B3B9-FF6396F2F033

Q27489398-51D414B3-5B4F-4A09-AD05-89DF5BC90AA5

Q27489398-7391B82F-4945-4A3E-BBC4-3C8DBFD5663C

Q27489398-8C7271E3-7BD0-48E9-8EC3-7BFA6B0234DA

P304

Q27489398-DF9A5A01-9F2A-42BA-BB5F-04653698634E

P31

Q27489398-08DAA6E3-EF46-454F-8FE1-73490DEF7EEE

P3181

Q27489398-93C7060B-9212-4C16-9E92-3A145CAADC17

P356

Q27489398-5D4D4C78-5B05-47B7-B75D-A7FF3C0AA565

P407

Q27489398-4CB0440C-AECE-4B4D-A0AC-C7F33F022A74

P433

Q27489398-69CA126D-0742-4399-A3ED-75237833D786

P478

Q27489398-CC225286-70F3-43FF-85B3-F08AC293822A

P50

Q27489398-657512BA-4FBB-44FD-B8EA-1AA605B9A52B

P577

Q27489398-D91E7ADD-CD7B-4014-8E7B-1081149C10F0

P5875

Q27489398-7FD03EF3-6087-4783-8FBE-FE73752F1630

P698

Q27489398-B7243313-65F9-42C4-9B68-1781FEE625FD

P921

Q27489398-C28A2CC5-4493-4BA4-A0C7-B3C208B4C3D5

Q27489398-DCD4CB59-EDF6-4F02-979B-66A58824D400

Q27489398-DFA40687-CB4C-4E69-8B77-2ADB190127EA

P932

Q27489398-A19750D0-8761-45CC-A253-8C1ABAA53D78

P3181

P356

P1433

P1476

Clinical, virologic, histologi ...... year follow-up of 150 patients

@en

P2093

Bruce R Bacon

http://www.w3.org/2001/XMLSchema#string

Elizabeth M Brunt

http://www.w3.org/2001/XMLSchema#string

Joyce Hoffmann

http://www.w3.org/2001/XMLSchema#string

Kusal L Mihindukulasuriya

http://www.w3.org/2001/XMLSchema#string

Sarah L George

http://www.w3.org/2001/XMLSchema#string

P2860

Performance Evaluation of the VERSANT HCV RNA Qualitative Assay by Using Transcription-Mediated Amplification

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond.

Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy.

Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy.

10-Year follow-up after interferon-alpha therapy for chronic hepatitis C.

Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon.

A comparison between the phenol-chloroform method of RNA extraction and the QIAamp viral RNA kit in the extraction of hepatitis C and GB virus-C/hepatitis G viral RNA from serum.

Long-term follow-up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver-related complications.

Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon-alpha 2b.

P304

729-38

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

782693

http://www.w3.org/2001/XMLSchema#string

P356

10.1002/HEP.22694

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

49

http://www.w3.org/2001/XMLSchema#string

P50

Adrian M. Di Bisceglie

P577

2009-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23653733

http://www.w3.org/2001/XMLSchema#string

P698

19072828

http://www.w3.org/2001/XMLSchema#string

P921

P932

2731713

http://www.w3.org/2001/XMLSchema#string